// App-Quantinova.ai

e14101 : Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors.

Researchers

Presenter

  • Matthias Machacek

Principal Investigators

  • Lionel Renaud

  • Sasa Dimitrijevic

  • Debora Schmitz

  • Elena Ivanova

  • Karin Jorga

Medical Centers

  • LYO-X GmbH, Allschwil, Switzerland

  • Piqur Therapeutics AG, Basel, Switzerland

  • Karin Jorga Life Science Consulting GmbH, Basel, Switzerland

Locations

  • Switzerland

Companies

  • LYO-X GmbH

  • Karin Jorga Life Sci

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • PQR309

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • I

Study Id's

  • NCT01940133

  • NCT02483858

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved